PMID- 12404881
OWN - NLM
STAT- MEDLINE
DCOM- 20021126
LR  - 20151119
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 52
IP  - 9
DP  - 2002
TI  - Human neutrophil oxidative bursts and their in vitro modulation by different 
      N-acetylcysteine concentrations.
PG  - 669-76
AB  - Reactive oxygen species released by activated polymorphonuclear leukocytes as an 
      expression of their defensive function are considered to be a major source of the 
      cytotoxic oxidant stress, that triggers a self-sustaining phlogogenic loop in the 
      respiratory system. N-Acetylcysteine (CAS 616-91-1, NAC), a known mucolytic drug, 
      possesses also antioxidant properties, but it undergoes a rapid and extensive 
      first-pass metabolism resulting in low tissue availability. Thus to further 
      improve the NAC bioavailability a single oral administration of 1200 mg NAC has 
      been recently proposed. This study has been performed to investigate in vitro by 
      means of luminol amplified chemiluminescence the ability of the concentration of 
      35 mumol/l NAC available after single oral administration of 1200 NAC to 
      interfere with human neutrophil oxidative burst evoked by both corpuscolate and 
      soluble stimulants, in comparison with 16 mumol/l NAC, the serum concentration 
      obtainable after single oral administration of 600 mg NAC. At concentrations of 
      16 and 35 mumol/l, NAC significantly reduced in a concentration-dependent manner 
      the activation of polymorphonuclear neutrophils (PMNs) oxidative bursts induced 
      by all of the stimulants (C. albicans, formyl-methionyl-leucyl-phenylalanine 
      (fMLP), phorbol myristate acetate (PMA)). This effect was also present in 
      cell-free systems, thus confirming the scavenger activity of these two 
      concentrations of NAC. The fact that no effects were seen on PMN phagocytosis and 
      bacterial killing indicates that NAC has no negative influence on other PMN 
      functions such as antimicrobial activity.
FAU - Allegra, Luigi
AU  - Allegra L
AD  - Department of Pharmacology, Institute of Respiratory Diseases, School of 
      Medicine, University of Milan, Milan, Italy.
FAU - Dal Sasso, Monica
AU  - Dal Sasso M
FAU - Bovio, Cinzia
AU  - Bovio C
FAU - Massoni, Carola
AU  - Massoni C
FAU - Fonti, Elena
AU  - Fonti E
FAU - Braga, Pier Carlo
AU  - Braga PC
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Free Radical Scavengers)
RN  - 0 (Oxidants)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - 5EXP385Q4F (Luminol)
RN  - 712K4CDC10 (Hypochlorous Acid)
RN  - BBX060AN9V (Hydrogen Peroxide)
RN  - EC 1.17.3.2 (Xanthine Oxidase)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/*pharmacology
MH  - Adult
MH  - Candida albicans/immunology
MH  - Cell-Free System
MH  - Dose-Response Relationship, Drug
MH  - Escherichia coli/immunology
MH  - Free Radical Scavengers/*pharmacology
MH  - Humans
MH  - Hydrogen Peroxide
MH  - Hypochlorous Acid
MH  - Immunity, Cellular/drug effects
MH  - Luminescent Measurements
MH  - Luminol
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - Neutrophils/*drug effects
MH  - Oxidants
MH  - Phagocytosis/drug effects
MH  - Respiratory Burst/*drug effects
MH  - Staphylococcus aureus/immunology
MH  - Xanthine Oxidase/metabolism
EDAT- 2002/10/31 04:00
MHDA- 2002/11/28 04:00
CRDT- 2002/10/31 04:00
PHST- 2002/10/31 04:00 [pubmed]
PHST- 2002/11/28 04:00 [medline]
PHST- 2002/10/31 04:00 [entrez]
AID - 10.1055/s-0031-1299949 [doi]
PST - ppublish
SO  - Arzneimittelforschung. 2002;52(9):669-76. doi: 10.1055/s-0031-1299949.